APLS Stock Overview
A commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Apellis Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$29.26 |
| 52 Week High | US$73.80 |
| 52 Week Low | US$24.34 |
| Beta | 0.87 |
| 11 Month Change | 7.81% |
| 3 Month Change | -18.77% |
| 1 Year Change | -39.22% |
| 33 Year Change | -37.89% |
| 5 Year Change | 1.28% |
| Change since IPO | 108.55% |
Recent News & Updates
Recent updates
Would Apellis Pharmaceuticals (NASDAQ:APLS) Be Better Off With Less Debt?
Oct 18
Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion
Oct 01Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues
Sep 27Apellis: Rare Kidney Disease Data Leads To Possible First To Market
Aug 09Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?
Jul 12What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You
May 30It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year
May 30Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks
May 14Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain
Feb 16With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For
Jul 19Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week
May 13Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?
Apr 18Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt Sensibly?
Dec 14Shareholder Returns
| APLS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.2% | 3.7% | 5.7% |
| 1Y | -39.2% | 29.2% | 36.9% |
Return vs Industry: APLS underperformed the US Biotechs industry which returned 29.2% over the past year.
Return vs Market: APLS underperformed the US Market which returned 36.9% over the past year.
Price Volatility
| APLS volatility | |
|---|---|
| APLS Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: APLS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: APLS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 704 | Cedric Francois | www.apellis.com |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development.
Apellis Pharmaceuticals, Inc. Fundamentals Summary
| APLS fundamental statistics | |
|---|---|
| Market cap | US$3.68b |
| Earnings (TTM) | -US$250.10m |
| Revenue (TTM) | US$715.22m |
5.1x
P/S Ratio-14.6x
P/E RatioIs APLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APLS income statement (TTM) | |
|---|---|
| Revenue | US$715.22m |
| Cost of Revenue | US$417.28m |
| Gross Profit | US$297.94m |
| Other Expenses | US$548.04m |
| Earnings | -US$250.10m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.01 |
| Gross Margin | 41.66% |
| Net Profit Margin | -34.97% |
| Debt/Equity Ratio | 190.7% |
How did APLS perform over the long term?
See historical performance and comparison